Ongericimab (JS002) is a recombinant humanized monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking the binding of PCSK9 to the low-density lipoprotein receptor (LDLR), the antibody reduces LDLR degradation, thereby increasing hepatic LDL-C uptake and lowering plasma cholesterol levels. It is primarily used to research hypercholesterolemia and cardiovascular risk management.